Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time
CompletedPhase 3NCT01240863
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The primary objective of this study is to evaluate efficacy of hydrocodone extended-release (ER) tablets compared with placebo in alleviating moderate to severe pain in patients with osteoarthritis or low back pain as assessed by the weekly Average Pain Intensity (API) at week 12.
Study details
- Official title
- A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) at 15 to 90 mg Every 12 Hours for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time
- Conditions
- Interventions
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Start date
- 2010-11
- Primary completion
- 2011-08
- Sex
- All
- Age range
- from 18 Years to 80 Years
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- United States
- Total sites listed
- 73
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * The patient is able to speak English and is willing to provide written informed consent, including a written opioid agreement, to participate in this study. * The patient must be willing and able to successfully self-administer the study drug, comply with study restrictions, complete the electronic diary, and return to the clinic for scheduled study visits as specified in this protocol. * Women of childbearing potential (not surgically sterile or 2 years postmenopausal), must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 30 days after participation in the study, and have a negative pregnancy test at screening. * The patient has pain of at least 3 months' duration associated with osteoarthritis or low back pain. * The patient reports an average pain intensity score, over the prior 24 hours, of 5 or more on the 11-point numerical rating scale. * If the patient is receiving physical therapy, biofeedback therapy, acupuncture therapy, or herbal remedies, these therapies must remain unchanged during the study. * The patient must not participate in other study involving an investigational agent while enrolled into the present study. Exclusion Criteria: * The patient has known or suspected hypersensitivities, allergies, or other contraindications to any ingredient in the study drug. * The patient has a recent history (within 5 years) or current evidence of alcohol or other substance abuse with the exception of nicotine or caffeine. * The patient has medical or psychiatric disease that, in the opinion of the investigator, would compromise collected data. * The patient is taking a total (ie, around-the-clock plus rescue medication) of more than 135 mg/day of oxycodone, or equivalent, during the 14 days prior to screening. * The patient has a history of suicidality. * The patient is expected to have surgery during the study. * The patient's primary painful condition under study is related to any source of chronic pain other than osteoarthritis or low back pain. * The patient is pregnant or lactating. * The patient has active malignancy. * The patient has human immunodeficiency virus (HIV). * In the judgment of the investigator, the patient has any clinically significant deviation from normal in the physical examination and/or clinical laboratory test values. * The patient has cardiopulmonary disease that would, in the opinion of the investigator, significantly…
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01240863